ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

EXAI Exscientia PLC

4.70
-0.39 (-7.66%)
04 May 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Exscientia PLC NASDAQ:EXAI NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  -0.39 -7.66% 4.70 2.35 10.50 5.24 4.67 5.21 631,951 05:00:10

Exscientia to Report Full Year 2022 Financial Results on March 23, 2023

16/03/2023 11:00am

Business Wire


Exscientia (NASDAQ:EXAI)
Historical Stock Chart


From May 2022 to May 2024

Click Here for more Exscientia Charts.

Company to host conference call and webcast on March 23, 2023 at 12:30 p.m. GMT / 8:30 a.m. EDT

Exscientia plc (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, March 23, 2023 before the open of U.S. markets. The Company will host a conference call and webcast at 12:30 p.m. GMT / 8:30 a.m. EDT to provide a business update and review financial results.

A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company’s website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 (888) 330 3292 (U.S.), +44 203 433 3846 (U.K.), +1 (646) 960 0857 (International) and entering the conference ID: 8333895. A replay will be available for 90 days under "Events and Presentations” in the “Investors and Media” section of the Exscientia website.

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.

Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

Investor Relations Contact: Sara Sherman investors@exscientia.ai Media Contact: Oliver Stohlmann media@exscientia.ai

1 Year Exscientia Chart

1 Year Exscientia Chart

1 Month Exscientia Chart

1 Month Exscientia Chart

Your Recent History

Delayed Upgrade Clock